Alkaloids from Cryptolepis sanguinolenta as Potential Inhibitors of SARS-CoV-2 Viral Proteins: An In Silico Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alkaloids from Cryptolepis sanguinolenta as Potential Inhibitors of SARS-CoV-2 Viral Proteins: An In Silico Study
Authors
Keywords
-
Journal
Biomed Research International
Volume 2020, Issue -, Pages 1-14
Publisher
Hindawi Limited
Online
2020-09-23
DOI
10.1155/2020/5324560
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID‐19: Lessons from SARS and MERS
- (2020) Mirae Park et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- Principle and design of pseudo-natural products
- (2020) George Karageorgis et al. Nature Chemistry
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
- (2020) Nature Microbiology
- Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants
- (2020) Gideon A. Gyebi et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease
- (2020) Tien Huynh et al. Journal of Physical Chemistry Letters
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- Structure of the RNA-dependent RNA polymerase from COVID-19 virus
- (2020) Yan Gao et al. SCIENCE
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
- (2020) Wanchao Yin et al. SCIENCE
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
- (2020) Bhumi Shah et al. LIFE SCIENCES
- COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
- (2020) Muhammad Adnan Shereen et al. Journal of Advanced Research
- Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
- (2019) Robert N. Kirchdoerfer et al. Nature Communications
- LARMD: integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor
- (2019) Jing-Fang Yang et al. BRIEFINGS IN BIOINFORMATICS
- SWISS-MODEL: homology modelling of protein structures and complexes
- (2018) Andrew Waterhouse et al. NUCLEIC ACIDS RESEARCH
- ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database
- (2018) Jie Dong et al. Journal of Cheminformatics
- Binding Affinity via Docking: Fact and Fiction
- (2018) Tatu Pantsar et al. MOLECULES
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
- (2017) Antoine Daina et al. Scientific Reports
- An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
- (2016) Thanigaimalai Pillaiyar et al. JOURNAL OF MEDICINAL CHEMISTRY
- ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
- (2015) James A. Maier et al. Journal of Chemical Theory and Computation
- Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses
- (2015) Kathleen C. Lehmann et al. NUCLEIC ACIDS RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started